关于公司申请银团贷款暨子公司及公司关联方提供担保的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆智飞生物制品股份有限公司（以下简称"公司"）于 2025 年 12 月 31 日召开第六届董事会第九次会议，审议通过《关于公司申请银团贷款暨子公司及 公司关联方提供担保的议案》，并与中国农业银行股份有限公司重庆江北支行作 为牵头行的银团签订了银团贷款协议，具体情况如下： 证券代码：300122 证券简称：智飞生物 公告编号：2026-02 重庆智飞生物制品股份有限公司 3、本次银团贷款担保方式为信用，并追加如下保证，质押，抵押：(1)蒋仁 生及其配偶，蒋凌峰及其配偶，智飞绿竹、智飞龙科马等子公司提供全额连带责 任保证担保。(2)上市公司以应收账款及所持智飞绿竹、智飞龙科马等子公司的 全部股权提供担保。(3)上市公司、智飞绿竹、智飞龙科马等子公司以其工业厂 房，办公楼及在建工程等提供担保。 4、上述银团贷款的具体参贷行、贷款金额、贷款期限、担保方式及条款内 容以各方最终签订的合同为准。 5、公司本次融资事项在股东会已审批的融资额度范围内，且公司以自身资 产 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 重庆智飞生物制品股份有限公司 第六届董事会第九次会议决议公告 1、本次董事会于 2025 年 12 月 31 日以专人送达的方式向董事发出通知。 2、本次会议于 2025 年 12 月 31 日 14:00 在公司会议室以现场结合通讯方式 召开。 3、本次会议应出席并参加表决的董事 9 人，实际出席并参加表决的董事 9 人。 证券代码：300122 证券简称：智飞生物 公告编号：2026-01 化公司债务结构，补充日常营运资金，加速推进研发项目进展，促进公司稳健经 营与发展。公司实际控制人蒋仁生先生及其配偶、其子蒋凌峰先生及其配偶为公 司本次融资提供无偿担保，构成关联交易。本次关联交易系公司关联方为了促进 公司稳健经营发展为公司融资提供的无偿担保，不存在侵害公司及其他非关联股 东特别是中小股东利益的情形。 具体内容详见公司发布在中国证监会指定信息披露网站巨潮资讯网的《关于 公司申请银团贷款暨子公司及公司关联方提供担保的公告》（2026-02）。 4、本次会议由公司董事长蒋仁生先生主持。 5 ...

Core Viewpoint - Chongqing Zhifei Biological Products Co., Ltd.'s subsidiary, Chongqing Chanan Biopharmaceutical Co., Ltd., has successfully completed the phase III clinical trial for CA508 injection, a dual insulin product for treating type 2 diabetes, demonstrating efficacy and safety comparable to the original drug [1][2]. Product Development Progress and Market Path - Following the completion of the phase III clinical trial, Chongqing Chanan Biopharmaceutical Co., Ltd. will submit a drug production registration application to the National Medical Products Administration, which must pass technical review and clinical site inspection before market approval [2]. - The successful development of CA508 injection signifies a significant breakthrough for Chongqing Chanan Biopharmaceutical Co., Ltd. in the diabetes treatment sector, with broad clinical application prospects [2]. Impact on Company Business Layout - Chongqing Zhifei Biological Products Co., Ltd. indicated that CA508 injection will not have a major short-term impact on overall company performance, but successful market approval could strengthen the company's treatment segment within its integrated "prevention & treatment" business layout [3]. - The strategic extension into therapeutic drugs, particularly in diabetes treatment, reflects the company's commitment to diversifying beyond its traditional vaccine business, laying a solid product foundation for long-term development [3].

Core Insights - The Chongqing Private Economy Innovation and Development Conference recognized Zhifei Biological Products Co., Ltd. for its outstanding performance in technological innovation, ranking 3rd in the "2025 Chongqing Private Enterprises Technology Innovation Index Top 100" and 4th in the "2025 Chongqing Private Enterprises R&D Investment Top 50" [1][3] Group 1: Company Achievements - Zhifei Biological has made significant advancements in its R&D projects, particularly in the preventive field, with two vaccines, including a quadrivalent influenza virus split vaccine, launched this year [2] - The company has 34 self-developed projects in the preventive field, with 24 in the application, clinical, or listing application stages [2] - In the therapeutic area, Zhifei has 8 self-developed projects, with 7 in clinical or registration stages, including liraglutide injection awaiting listing application [2] Group 2: R&D Investment and Strategy - Over the past three years, Zhifei Biological has invested more than 6 billion yuan in R&D, reflecting its strong commitment to understanding market demands and technological trends [1][2] - The company follows an innovation strategy of prioritizing independent R&D, supplemented by collaborative R&D and investment incubation, which has laid a solid foundation for its sustainable development [1] Group 3: Future Outlook - Zhifei Biological aims to strengthen its position as an innovation leader, focusing on core technologies and addressing public health needs to contribute to the high-quality development of the biopharmaceutical industry and the construction of a healthy China [3]

Core Insights - The project initiated by the China Cancer Foundation and supported by Merck aims to implement a comprehensive cervical cancer prevention program in low-resource areas of China, starting in Shanxi Province [1][4] - Merck has donated a total of 81,000 doses of HPV vaccines to the China Cancer Foundation, which will be distributed for free vaccination of eligible middle school girls in various provinces [1][2] - The project is significant for reducing the burden of HPV-related diseases and is aligned with China's goal of eliminating cervical cancer as part of the Healthy China initiative [1][4] Group 1: Project Implementation - The cervical cancer prevention project officially launched on December 29, 2023, after nearly six months of preparation, including training healthcare personnel and conducting surveys [1][4] - The project specifically targets middle school girls, as vaccination at a younger age is believed to elicit a better immune response and provide more effective protection [3][4] - The initiative is part of a broader strategy to address the rising incidence of cervical cancer in China, particularly among younger women [2][3] Group 2: Public Health Context - HPV infection is a major health threat for women in China, with the country reporting the highest number of cervical cancer cases globally in 2022 [2] - The World Health Organization has emphasized the importance of HPV vaccination as a key preventive measure against cervical cancer, which is increasingly recognized as a public health issue in China [2][3] - The project aligns with the WHO's global strategy to accelerate the elimination of cervical cancer and China's own action plan for 2023-2030 [2][4]

Core Viewpoint - The announcement indicates that Zhifei Biological's subsidiary, Chongqing Chen'an Biological Pharmaceutical Co., Ltd., has completed the Phase III clinical trial summary report for the insulin injection CA508, demonstrating comparable efficacy and safety to the original drug, NovoRapid® [1] Group 1: Clinical Trial Results - The CA508 insulin injection has shown effectiveness and safety comparable to the original NovoRapid® insulin injection [1] - The clinical trial design meets the requirements outlined in the "Guidelines for Clinical Trials of Diabetes Drugs and Biological Products" regarding efficacy and safety evaluation [1] Group 2: Market Context - As of the announcement date, there is only one other domestic company that has received approval for a similar insulin injection product [1]

Core Viewpoint - The announcement by Zhifei Biological indicates a significant breakthrough in the treatment of metabolic diseases, specifically with the completion of Phase III clinical trials for the CA508 insulin injection, which lays the groundwork for future market approval [1] Group 1: Clinical Trial Results - The CA508 injection, developed by the subsidiary Chuanan Biological, has completed Phase III clinical trials and received a summary report, marking a key milestone for the company in the diabetes treatment sector [1] - The clinical trial was led by Peking University People's Hospital and involved 40 domestic research centers, focusing on Type 2 diabetes patients with inadequate insulin treatment [1] - Results show that CA508 injection is comparable in efficacy and safety to the original drug (NovoRapid®), meeting relevant guidelines and providing core evidence for registration [1] Group 2: Product Details - CA508 injection is a new generation of basal-bolus insulin formulation, combining degludec insulin and aspart insulin, which allows for dual control of basal and postprandial blood glucose levels [1] - The formulation is a clear solution that requires 1-2 daily injections without the need for mixing, enhancing patient compliance [1] Group 3: Market Implications - Currently, there is only one other similar product approved in the domestic market aside from the original drug, indicating a potential competitive advantage for CA508 if approved [1] - The successful launch of CA508 injection would further solidify the company's integrated "prevention & treatment" strategy, strengthening its market position and industry competitiveness [1]

Core Viewpoint - Chongqing Zhifei Biological Products Co., Ltd. has achieved a significant breakthrough in the treatment of metabolic diseases with the successful completion of Phase III clinical trials for its CA508 injection, paving the way for future product registration [1][2]. Group 1: Product Development - The CA508 injection is a new generation of dual insulin formulation, combining long-acting insulin (degludec) and rapid-acting insulin (aspart), which allows for precise control of both baseline and postprandial blood sugar levels while significantly reducing the risk of hypoglycemia [2]. - The formulation is designed for ease of use, requiring only 1-2 injections per day without the need for mixing prior to use, thereby improving patient compliance [2]. Group 2: Clinical Trial Details - The Phase III clinical trial was led by Peking University People's Hospital and involved 40 research centers across China, employing a multi-center, randomized, open-label, parallel-controlled design [2]. - The trial focused on type 2 diabetes patients who had poor blood sugar control after previous treatment with basal or premixed insulin, addressing an unmet clinical need [2]. - The clinical trial summary report indicates that CA508 injection's efficacy and safety are comparable to the original drug, providing a solid basis for subsequent registration applications [2]. Group 3: Market Landscape - As of the announcement date, only one other company has a similar product approved in the domestic market, positioning CA508 injection as a promising local innovative treatment option for type 2 diabetes patients [3]. - Zhifei Biological aims to accelerate the transformation of research results into practical applications, guided by public health needs [3].

Core Viewpoint - The company Zhifei Biological (300122.SZ) announced that its subsidiary, Chongqing Chanan Biopharmaceutical Co., Ltd., has completed the phase III clinical trial summary report for its insulin injection product, CA508, which shows comparable efficacy and safety to the original drug, NovoRapid® [1] Group 1 - The CA508 insulin injection has met the design requirements for efficacy and safety evaluation as per the Clinical Trial Guidelines for Diabetes Drugs and Biological Products [1] - The product demonstrates effectiveness and safety on par with the original NovoRapid® insulin injection [1]

Core Viewpoint - The company Zhifei Biological (300122.SZ) announced that its subsidiary, Chongqing Chen'an Biological Pharmaceutical Co., Ltd., has completed the phase III clinical trial summary report for the insulin injection CA508, which shows comparable efficacy and safety to the original drug NovoRapid [1] Group 1 - The CA508 insulin injection has met the design requirements for efficacy and safety evaluation as per the guidelines for clinical trials of diabetes medications and biological products [1] - The clinical trial results indicate that CA508 is on par with the original NovoRapid insulin injection in terms of effectiveness and safety [1]